![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
Interleukin-6 receptor antagonist treatment improves outcomes in patients with COVID-19 infection [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Tag: Tocilizumab
The EMPACTA trial: Tocilizumab reduced COVID-19 disease-related adverse health outcomes [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
#VisualAbstract: Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated ...
Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated ...
#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome ...
Tocilizumab reduced COVID-19 disease related adverse health outcomes
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome ...
Interleukin-6 receptor antagonist treatment improves outcomes in COVID-19 patients
1. Treatment with tocilizumab and sarilumab increased the number of days without respiratory or cardiovascular organ support in patients with ...
#VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. ...
#VisualAbstract: Tocilizumab not superior to standard care in randomized controlled trial for severe COVID-19 patients
1. Tocilizumab was not superior to standard care after 15 days, for COVID-19 patients in serious condition. 2. Patients given ...
Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. ...